2023 - Research.com Medicine in Belgium Leader Award
His main research concerns Internal medicine, Breast cancer, Oncology, Surgery and Metastatic breast cancer. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Gynecology. His Breast cancer research incorporates elements of Tumor progression, Clinical trial, Pathology and Metastasis.
His Oncology study incorporates themes from Antiestrogen, Exemestane, Tamoxifen and Trastuzumab. His Surgery research integrates issues from Placebo and Family medicine. In his research, Bevacizumab is intimately related to Docetaxel, which falls under the overarching field of Metastatic breast cancer.
Luc Dirix mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Cancer research. The various areas that Luc Dirix examines in his Internal medicine study include Gastroenterology and Surgery. His studies examine the connections between Oncology and genetics, as well as such issues in Circulating tumor cell, with regards to Prostate cancer.
Luc Dirix combines subjects such as Hazard ratio, Gene expression profiling and Pathology with his study of Breast cancer. His Pathology research includes themes of Angiogenesis and Metastasis, Lymphangiogenesis. His Cancer research research includes elements of Gene expression and Gene.
Internal medicine, Oncology, Cancer research, Breast cancer and Cancer are his primary areas of study. His work on Chemotherapy, Clinical trial, Metastatic breast cancer and Cohort as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His work deals with themes such as Circulating tumor cell, Adverse effect, Proportional hazards model, Biomarker and Prostate cancer, which intersect with Oncology.
Luc Dirix has included themes like Cell culture, E2F1, Cistrome, Inflammatory breast cancer and Gene in his Cancer research study. His Breast cancer research focuses on subjects like Hazard ratio, which are linked to Placebo. His Cancer study integrates concerns from other disciplines, such as Cytotoxic T cell and PI3K/AKT/mTOR pathway.
The scientist’s investigation covers issues in Internal medicine, Oncology, Clinical trial, Avelumab and Prostate cancer. His research on Internal medicine frequently links to adjacent areas such as Surgery. His Oncology study combines topics from a wide range of disciplines, such as Circulating tumor cell, Metastatic breast cancer, Sonidegib, Pathology and Triple-negative breast cancer.
His Clinical trial research is multidisciplinary, relying on both Survival analysis and Chemotherapy. His work in Prostate cancer tackles topics such as Clinical significance which are related to areas like Mrna expression, Cabazitaxel, Taxane and Median time. Inflammatory breast cancer is the focus of his Breast cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal;Serena Nik-Zainal;Helen Davies;Johan Staaf;Manasa Ramakrishna.
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic;Michael R. Migden;Anthony E. Oro;Luc Dirix.
The New England Journal of Medicine (2012)
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés.
Journal of Clinical Oncology (2010)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian.
The Lancet (2017)
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation
P. E. Vermeulen;G. Gasparini;S. B. Fox;Masakazu Toi.
European Journal of Cancer (1996)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
François-Clément Bidard;François-Clément Bidard;Dieter Peeters;Tanja Fehm;Franco Nolé.
Lancet Oncology (2014)
Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial
M Kaufmann;E Bajetta;L Y Dirix;L E Fein.
Journal of Clinical Oncology (2000)
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.
P.B. Vermeulen;G. Gasparini;S.B. Fox;C. Colpaert.
European Journal of Cancer (2002)
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M. Aapro;P. A. Abrahamsson;J. J. Body;R. E. Coleman.
Annals of Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: